Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration

García-Quintanilla, Laura; Luaces-Rodríguez, Andrea; Gil-Martínez, María; Mondelo-García, Cristina; Maroñas, Olalla; Mangas-Sanjuan, Víctor; González-Barcia, Miguel; Zarra-Ferro, Irene; Aguiar, Pablo; Otero-Espinar, Francisco J.; Fernández-Ferreiro, Anxo

doi:10.3390/pharmaceutics11080365

Submit to this Journal Review for this Journal Edit a Special Issue

Article Menu

...

Open AccessReview

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration

Laura García-Quintanilla

^1,2,†,

Andrea Luaces-Rodríguez

^2,3,†

María Gil-Martínez

⁴,

Cristina Mondelo-García

^1,2,

Olalla Maroñas

⁵,

Víctor Mangas-Sanjuan

^6,7

Miguel González-Barcia

^1,2,

Irene Zarra-Ferro

^1,2,

Pablo Aguiar

^8,9

Francisco J. Otero-Espinar

^3,*

and

Anxo Fernández-Ferreiro

^1,2,3,*

Pharmacy Department, University Clinical Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain

Pharmacology Group, Health Research Institute of Santiago de Compostela (FIDIS), 15706 Santiago de Compostela, Spain

Department of Pharmacology, Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Santiago de Compostela (USC), 15782 Santiago de Compostela, Spain

⁴

Ophthalmology Department, University Clinical Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain

⁵

Genomic Medicine Group, Galician Public Foundation of Genomic Medicine, Health Research Institute of Santiago de Compostela (FIDIS), 15706 Santiago de Compostela, Spain

⁶

Department of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, 46100 Valencia, Spain

⁷

Interuniversity Research Institute for Molecular Recognition and Technological Development, Polytechnic University of Valencia, 46100 Valencia, Spain

⁸

Nuclear Medicine Department, University Clinical Hospital of Santiago de Compostela (SERGAS), 15706 Santiago de Compostela, Spain

⁹

Molecular Imaging Group, Health Research Institute of Santiago de Compostela (FIDIS), 15706 Santiago de Compostela, Spain

Authors to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Pharmaceutics 2019, 11(8), 365; https://doi.org/10.3390/pharmaceutics11080365

Received: 30 June 2019 / Revised: 20 July 2019 / Accepted: 22 July 2019 / Published: 31 July 2019

(This article belongs to the Special Issue Recent Application of Pharmacokinetics in Drug Development and Drug Therapy)

View Full-Text Download PDF

Browse Figures

Citation Export

Abstract

Intravitreal administration of anti-vascular endothelial growth factor (VEGF) antibodies has become the standard treatment for Age-Related Macular Degeneration; however, the knowledge of their pharmacokinetics is limited. A comprehensive review of the preclinical and clinical pharmacokinetic data that were obtained in different studies with intravitreal bevacizumab, ranibizumab, and aflibercept has been conducted. Moreover, the factors that can influence the vitreous pharmacokinetics of these drugs, as well as the methods that were used in the studies for analytical determination, have been exposed. These anti-VEGF drugs present different charge and molecular weights, which play an important role in vitreous distribution and elimination. The pharmacokinetic parameters that were collected differ depending on the species that were involved in the studies and on physiological and pathological conditions, such as vitrectomy and lensectomy. Knowledge of the intravitreal pharmacokinetics of the anti-VEGF drugs that were used in clinical practice is of vital importance. View Full-Text

Keywords: vascular endothelial growth factor/antagonists & inhibitors; ranibizumab; aflibercept; bevacizumab; Age-Related Macular Degeneration; pharmacokinetics; intravitreal

▼ Show Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Share and Cite

MDPI and ACS Style

García-Quintanilla, L.; Luaces-Rodríguez, A.; Gil-Martínez, M.; Mondelo-García, C.; Maroñas, O.; Mangas-Sanjuan, V.; González-Barcia, M.; Zarra-Ferro, I.; Aguiar, P.; Otero-Espinar, F.J.; Fernández-Ferreiro, A. Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration. Pharmaceutics 2019, 11, 365. https://doi.org/10.3390/pharmaceutics11080365

AMA Style

García-Quintanilla L, Luaces-Rodríguez A, Gil-Martínez M, Mondelo-García C, Maroñas O, Mangas-Sanjuan V, González-Barcia M, Zarra-Ferro I, Aguiar P, Otero-Espinar FJ, Fernández-Ferreiro A. Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration. Pharmaceutics. 2019; 11(8):365. https://doi.org/10.3390/pharmaceutics11080365

Chicago/Turabian Style

García-Quintanilla, Laura, Andrea Luaces-Rodríguez, María Gil-Martínez, Cristina Mondelo-García, Olalla Maroñas, Víctor Mangas-Sanjuan, Miguel González-Barcia, Irene Zarra-Ferro, Pablo Aguiar, Francisco J. Otero-Espinar, and Anxo Fernández-Ferreiro. 2019. "Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration" Pharmaceutics 11, no. 8: 365. https://doi.org/10.3390/pharmaceutics11080365

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

Pharmacokinetics of Intravitreal Anti-VEGF Drugs in Age-Related Macular Degeneration

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI